NYSE
$0.5585▲ 1.86%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $12.0MShares out 21.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 10.6Pre-market26.10.06 20:308-KKey event#●●●#●●●
Kairos Pharma, LTD.Bullish
Kairos Pharma reported positive, statistically significant interim efficacy data from its Phase 2 clinical trial of ENV-105 in combination with apalutamide for metastatic castration-resistant prostate cancer. The combination therapy achieved a median progression-free survival (PFS) of 17.7 months, compared to 2 months for apalutamide alone. Following these results, the company has modified its trial protocol to expand patient enrollment, targeting completion of the Phase 2 trial by the fourth quarter of 2027.…more
$0.5585+1.86%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.14After-hours26.09.15 05:008-KKey event
Kairos Pharma, LTD.
Kairos Pharma released a new investor presentation in conjunction with its participation in the H.C. Wainwright 28th Annual Global Investment Conference held from September 14-16, 2026. CEO John Yu will present the update on the company's clinical programs and business activities during the event.…more
$0.5585+1.86%vs prev closeView filingShare - 8.21After-hours26.08.22 05:308-KKey event
Kairos Pharma, LTD.
Kairos Pharma will execute a 1-for-7 reverse stock split of its common stock effective September 1, 2026, to maintain compliance with NYSE American listing requirements. The split will reduce the number of outstanding shares and proportionately increase the per-share trading price. Shareholders are not required to take any action, and fractional shares will be rounded up to the nearest whole share.…more
$0.5585+1.86%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.6Regular26.10.07 03:13#●●●#●●●#●●●
Kairos Pharma Reports Phase 2 Interim Results for Prostate Cancer Drug
Kairos Pharma announced positive interim Phase 2 results showing improved progression-free survival for its prostate cancer candidate ENV-105. Despite the clinical data, the company's shares fell to a 52-week low following protocol modifications.…more
$0.5585+1.86%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.6Pre-market26.10.06 20:31
●●●●●●●● ●●●●● ●●●●●●
Kairos Pharma announced that its prostate cancer drug candidate ENV-105 achieved a median progression-free survival of 17.7 months in Phase 2 trials, compared to 2 months. Investors should monitor further clinical progress as these are only interim results.…more
$0.5585+1.86%vs prev closeShareBenzinga - 8.24Overnight26.08.24 15:30
●●●●●●●● ●●●●● ●●●●●●
PDD Holdings is scheduled to report its quarterly earnings, while Applied Optoelectronics announced a $600 million at-the-market equity offering. Investors are closely monitoring these corporate developments as market volatility continues.…more
$0.5585+1.86%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report